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The bone marrow (BM) microenvironment (niche) plays important roles in supporting normal/
abnormal haematopoiesis. We investigated the interaction between leukaemic mesenchymal niche
and haematopoietic stem and progenitor cells (HSPCs) using the model of Fanconi anaemia (FA),
a genetic disorder characterized by BM failure and leukaemia. Healthy donor HSPCs co-cultured
on mesenchymal stromal cells (MSCs) derived from FA patients with acute myeloid leukaemia
(AML) exhibited higher human engraftment and myeloid expansion in Non-obese diabetic severe
combined immunodeficiency IL-2γ−/−/SGM3 recipients. Untargeted metabolomics analysis
revealed the progressively elevated prostaglandins (PGs) in the MSCs of FA patients with
myelodysplastic syndromes (MDS) and AML. Reduced secretion of PGs subsequent to
inflammatory cyclooxygenase 2 (COX2) inhibition ameliorated HSPC/myeloid expansion.
Transcriptome analysis demonstrated dysregulation of genes involved in the NR4A family of
transcription factors (TFs) and WNT/β-catenin signalling pathway in FA-AML-MSC-co-culturedCD34+ cells. COX2 inhibition led to significantly decreased NR4A TFs and WNT signalling
genes expression. Mechanistically, NR4A1 and NR4A2 synergistically activate the CTNNB1 gene
promoter. Knocking down CTNNB1 or NR4A1 in AML-MSC-co-cultured-CD34+ cells increased
leukaemia-reactive T-effector cells production and rescued anti-leukaemia immunity. Together,
these findings suggest that specific interactions between leukaemic mesenchymal niche and
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HSPCs orchestrate a novel COX2/PG-NR4A/WNT signalling axis, connecting inflammation,
cellular metabolism and cancer immunity.

Keywords
haematopoietic stem cell transplantation; mesenchymal stromal cells; prostaglandins; nuclear
hormone transcription factors; WNT signalling
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Haematopoietic stem cell transplantation (HSCT) is a potential curative therapy for patients
with high-risk haematological malignancies (van den Brink & Burakoff, 2002; Nikiforow &
Ritz, 2016), including Fanconi anaemia (FA), a cancer-prone disease associated with bone
marrow (BM) failure and leukaemia (Bagby & Alter, 2006; Dong et al, 2015). During the
last several decades, there have been major advances in FA HSCT due to significant
improvement in patient and donor selection (human leucocyte antigen [HLA] typing),
conditioning regimens, graft manipulation methods, graft-versus-host disease (GVHD)
prophylaxis and supportive care (de la Fuente et al, 2003; Dalle, 2008; MacMillan et al,
2011). However, overall survival rates of FA patients after HSCT are still below 30% and the
eradication of residual leukaemia stem cells (LSCs), which often contributes to relapse (van
den Brink & Burak-off, 2002), remains a major challenge.
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Haematopoietic stem cells (HSCs) and LSCs are supported by BM stromal cells and other
additional factors, which form the BM microenvironment (niche), to preserve their shared
characteristics, including quiescence, multipotency and self-renewal (Wilson & Trumpp,
2006). Recent studies have revealed that disordered niche function could contribute to
disease. For example, several studies show that altered signalling in the BM stroma/niche
can result in leukaemia initiation or progression (Walkley et al, 2007; Raaij-makers et al,
2010; Zhang et al, 2012; Morrison & Scadden, 2014). Conversely, leukaemic cells can
reprogramme the BM niche in favour of leukaemic proliferation while compromising normal
haematopoiesis (Kode et al, 2014). To date, only a few studies have described the functional
characteristics of FA BM mesenchymal stromal cells (MSCs; Smyth et al, 2009; Schepers et
al, 2013; Fontaine et al, 2016), all of which implicate a role of the FA BM niche in the
pathophysiology of FA BM failure. However, the role of the FA BM niche in the
maintenance of the residue LSCs and leukaemia relapse after HSCT has not been defined.

Author Manuscript

Prostaglandins (PGs) are lipid compounds of the eicosanoid family, which play major roles
in inflammation and immune response (Smyth et al, 2009) and are an important component
of the mesenchymal secretome (Fontaine et al, 2016). Synthesized by the pro-inflammatory
cyclooxygenases COX1 and COX2 through oxidation of the derivative arachidonic acid,
major PGs include PGE2, PGG2, PGH2 and PGI2 (Smith et al, 2000). Among them, PGE2
has been subjected to intensive investigation for its role in HSC expansion and engraftment
in the context of HSCT (Durand & Zon, 2010; Hoggatt & Pelus, 2010). In the context of
cancer, the key inflammatory enzyme for the biosynthesis of PGs, COX2 has long been
known to be deregulated in many cancers (Gallo et al, 2002; Wu et al, 2010; Janakiram &
Rao, 2014; Sicking et al, 2014). Inhibition of COX2 using either non-steroidal antiinflammatory drugs (NSAIDs) or specific COX2 inhibitors has been shown to be beneficial
for the treatment of a variety of solid tumours (Ranger, 2014). It is also been shown that
Br J Haematol. Author manuscript; available in PMC 2019 November 01.
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various oncogenes can induce expression of COX2 in haematopoietic cells and clinical
human leukaemias uniformly express COX2 in circulating blasts (Bernard et al, 2008).
COX2 selective inhibitors reduce the burden of haematological malignancies (Lilly et al,
2004; Ramon et al, 2013); however, the underlying mechanisms remain to be elucidated.
In the present study, we investigated the interaction between leukaemic mesenchymal niche
and haematopoietic stem and progenitor cells (HSPCs) using ex vivo co-culture and in vivo
xenotransplant, and identified a novel COX2/PG-NR4A/WNT signalling axis as a crucial
regulator of leukaemic mesenchymal niche-HSPC interaction. Our results suggest that
specific interaction between the leukaemic mesenchymal niche and HSPCs orchestrates this
novel immunometabolic axis, connecting inflammation, cellular metabolism and cancer
immunity, and that targeting this regulatory axis might be beneficial for developing
innovative therapeutic strategies for leukaemia and other haematological malignancies.

Author Manuscript

Materials and methods
Mice
Non-obese diabetic severe combined immunodeficiency (NOD/SCID)/rL2γ−/−/SGM3
(NSGS) mice, which express transgenic cDNAs encoding human stem cell factor (SCF, also
termed KITLG), granulocyte-macrophage colony-stimulating factor (GM-CSF), and
interleukin 3 (IL3) (Wunderlich et al, 2010) were purchased from Jackson Laboratory and
housed in Transgenic Animal Facility at West Virginia University (WVU). NSGS mice at
age of 6–8 weeks were used as recipients for BM transplantation (BMT). All experimental
procedures conducted in this study were approved by the Institutional Animal Care and Use
Committee of West Virginia University.

Author Manuscript

Human bone marrow stromal cell (hBMSC) culture and treatment
Human MSC culture protocol was adapted and modified from a previously described
method (Mirsaidi et al, 2017). Briefly, cell cultures were maintained at 37°C, in 5% CO2 and
98% humidity in normal growth medium consisting of Dulbecco’s modified eagle medium
(DMEM-low glucose, with GlutaMAX; ThermoFisher Scientific, Reinach, Switzerland),
supplemented with 10% fetal bovine serum (FBS; Sigma-Aldrich, St Louis, MO, USA),
penicillin/streptomycin (50 units/ml; 50 μg/ml). All MSCs were used at passage 3, which
displayed the characteristic MSC surface phenotype (CD45−HLA−DR
−CD105+CD73+CD90+CD44+CD146+).

Author Manuscript

To inhibit PG biosynthesis, MSCs derived from FA patients with acute myeloid leukaemia
(FA-AML) were pre-treated with COX2 inhibitor (COX2i; celecoxib, 10 μmol/l) for 2 h
(Rezavand et al, 2013) followed by co-culture with normal BM CD34+ cells for 2 weeks.
Cell culture media containing the specified treatment agents was regularly replenished every
3–4 days throughout the course of the experiment.
Bone marrow haematopoietic stem progenitor cell (HSPC)-MSC coculture
1–2 × 106 BM CD34+ cells from healthy donors (HD) were seeded on 70% confluent MSCs
derived from different sources and cultured in serum-free medium containing 100 ng/ml
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each of SCF, FLT3 ligand, thrombopoietin (TPO, also termed THPO) and granulocyte
colony-stimulating factor (G-CSF) for 2 weeks, followed by flow cytometry, colony-forming
unit cell (CFU-C) assay or BMT.
NSGS BMT and in vivo treatment
5 × 105 normal BM CD34+ cells from the co-culture on MSCs of HD, FA patients with
cytopenias but no cancer (FA-BMF) or FA-AML were transplanted into sublethallyirradiated (250 cGy) NSGS mice. Recipients were intraperitoneally (i.p.) injected with the
GVHD inhibitor, OKT3 (10 μg/kg; BioXCell, West Lebanon, NH, USA) at 24 h and 1 week
after transplant (Wunderlich et al, 2014). Total human engraftment (hCD45+), HSPCs
(CD34+) and myeloid (CD33+)/lymphoid (CD19+) cells of the recipients were analysed by
flow cytometry.

Author Manuscript

For in vivo treatment, NSGS mice transplanted with HD MSC co-cultured HSPCs were
subjected to i.p. injection of a long-acting agonist of PGE2, 16–16 dimethyl-PGE2
(dmPGE2; 10 μg/kg body weight; Cayman Chemical, Ann Arbor, MI, USA; Goessling et al,
2009) or vehicle (Neat oil) followed by flow cytometry analysis for donor-derived chimera
or different lineages at 12 weeks post-transplant.
Flow cytometry analysis

Author Manuscript

Bone marrow cells isolated from NSGS recipients were subjected to flow cytometry analysis
using antibodies for human CD45 for total human engraftment, CD34 for human progenitor
frequency, and CD33 and CD19 for myeloid or lymphoid lineage, respectively (BD
Biosciences, San Jose, CA, USA). The frequency of regulatory T cells (Treg) or effector T
cells (Teff) were determined by staining BM cells from the indicated experimental animals
with antibodies against CD4, CD25, FOXP3 or CD3, CD8 and CCR7 (BD Biosciences).
Metabolite profiling

Author Manuscript

Metabolites were extracted as previously described (Amarachintha et al, 2015). Briefly,
MSCs were washed with ice cold Dulbecco’s PBS twice to remove any culture media. Cells
were collected into 300-μl LC/MS-grade H2O containing 1 mmol/l HEPES and 1 mmol/l
EDTA (pH 7·2). Samples were vortexed for 30 s and incubated for 1–2 min in boiling water
and subsequently in liquid nitrogen for 1 min. Samples were then thawed on ice and
normalized based on the protein content. 2 ml of −20°C metabolite extraction solution
containing methanol, acetonitrile and H2O at a ratio of 2:2:1 was added to each sample and
vortexed for 1 min. Samples were then incubated at 4°C for 30 min followed by
centrifugation at 1500 g for 10 min. The supernatants (~2 ml total) were pooled in a high
performance liquid chromatography vial (Catalogue number 27115-U; Sigma-Aldrich) and
dried under forced nitrogen at room temperature before reconstituted for liquid
chromatography - quadrupole - time of flight - mass spectrometry (LC-Q-TOF-MS)
analysis. All pure standards were purchased from Sigma-Aldrich. Samples were
resuspended in 50 μl of 50:50 water/acetonitrile solutions for mass spectrometry analysis.
Untargeted metabolomics was performed on the MSC extract to identify which metabolite
levels are altered in MSCs derived from FA-MDS or FA-AML patients compared to those
from healthy donor MSCs. Samples analysed at Scripps Center for Metabolomics and Mass
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Spectrometry (La Jolla, CA, USA). LC-Q-TOF-MS detected hundreds of peaks with unique
m/z ratio and retention time in MSCs. Each peak, termed a metabolomics feature, is
characterized on the basis of its accurate mass, retention time and tandem mass spectral
fragmentation pattern by using the METLIN metabolite database (https://
metilin.scripps.edu). The data was then analysed with the bioinformatics program XCMS
online (Amarachintha et al, 2015), widely used XCMS software that is freely available at
https://xcmsonline.scripps.edu/landing_page.php?pgcontent=mainPage.
Prostaglandins assessment

Author Manuscript

Prostaglandin levels in the indicated MSCs were measured by enzyme-linked
immunosorbent assay (ELISA; Cayman Chemical, Ann Arbor, MI, USA) as previously
described (Rozenberg et al, 2016). Cells were seeded in 6-well plates and allowed to reach
90% confluence and then treated with 6MV-X-ray in growth medium without supplements
for the indicated times. In each condition, PGs were determined in supernatants by ELISA
following manufacturer directions using BioTEK ELX808 Absorbance Microplate Readers
(BioTEK, Winooski, VT, USA). Each condition was evaluated for PGs by averaging a
minimum of two optical density measurements. Measured ELISA test value from
supernatant of MSC for standard results were taken as the value for the 10 × 104 per MSCs.
Reporter gene assays
Approximately 106 HEK 293 cells were co-transfected with the indicated combinations of a
CTNNB1 reporter construct containing −591 to +147 of the proximal CTNNB1 promoter
(Zhou et al, 2008) and NR4A TFs, and plated on a 6-well plate. The cells were harvested 12
h after transfection, washed with PBS, and luciferase activity was assessed using the dual
luciferase assay reporter kit (Promega, Madison, WI, USA).

Author Manuscript

Cytotoxic T lymphocyte (CTL) cytotoxicity assay
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A semi-automated mini-cytotoxicity assay was used to determine specific lysis as previously
described (Molldrem et al, 2000). Effector cells (peripheral blood mononuclear cells; PBMC
or sorted CTLs) were prepared in doubling dilutions from 2·5 × 103 to 20 × 103 cells/well
and were plated in 40 μl, 60-well Terasaki trays (Robbins Scientific, Sunnyvale, CA, USA)
with six replicates per dilution. Target cells (BM cells from HLA-mismatched AML
patients) at a concentration of 2 × 106 cells/ml were stained with 1 μg/ml of Calsein-AM
(Molecular Probes, Eugene, OR, USA) for 60 min at 37°C. After washing three times in
culture medium plus 10% AB serum, target cells were re-suspended at 105 cells/ml. Wells
with target cells alone and medium alone were used for maximum (max) and minimum
(min) fluorescence emission, respectively. After a 4-h incubation at 37°C in 5% CO2, 5 μl
FluoroQuench (One Lambda, Canoga Park, CA, USA) was added to each well and the trays
were centrifuged for 1 min at 60 g before measurement of fluorescence (excitation at 485
nm, emission measured at 530 nm) using an automated CytoFluor II plate reader (PerSeptive
Biosystems, Foster City, CA, USA). A decrease in the fluorescence emission is proportional
to the degree of lysis of target cells, once the released dye was quenched by the haemoglobin
contained in the FluoroQuench reagent. The percentage of lysis was calculated as follows:
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%lysis = 1 − mean experimental emission − mean min/mean max − mean min × 100% .

Statistical analysis
Paired or unpaired Student’s t-test was used for two-group comparisons. Survival data were
plotted by the Kaplan–Meier curve method and analysed by the log-rank test. Values of P <
0·05 were considered statistically significant. Results are presented as mean ± SD. Detailed
methods are included in Appendix S1.

Results
FA-AML MSCs promote HSPC and myeloid expansion of normal BM CD34+ cells

Author Manuscript

To investigate the haematopoietic supportive function of FA MSCs in the context of disease
progression, we co-cultured normal BM CD34+ cells on MSCs derived from HD, FA-BMF,
or FA-AML, and then analysed the proliferation of the co-cultured HSPCs. We found that
total CD34+ progeny and CFU-C were significantly expanded on all three groups of MSCs
after 2 weeks of co-culture (Table S1). These results suggest that the ability of FA MSCs to
expand normal CD34+ ex vivo is not compromised. Furthermore, FA-AML showed the
greatest ability to expand the normal human BM HSPCs.

Author Manuscript

We next determined the effect of FA MSCs on the in vivo repopulating ability of the cocultured HSPCs by transplanting the co-cultured cells into sublethally-irradiated NSGS
mice, which express transgenic cDNAs encoding human SCF, GM-CSF and IL3
(Wunderlich et al, 2010). We have successfully used these “humanized” mice to establish the
FA AML xeno-transplant model (Du et al, 2011). Analysis of human engraftment at 12
weeks post-transplant revealed that the recipients transplanted with cells co-cultured on FABMF MSCs gave nearly the same total (hCD45+) and CD34+ engraftment as those receiving
cells co-cultured on HD MSCs (Fig 1). This suggests that the ability of these FA-BMF
MSCs to support haematopoietic repopulation in vivo is not compromised. Significantly, the
recipients of HSPCs co-cultured on the FA-AML MSCs not only exhibited much higher
total (hCD45+) and CD34+ engraftment than the other two groups, but also showed
characteristics of myeloid expansion at the expense of the lymphoid lineage (Fig 1A). The
observed HSPC/myeloid expansion promoted by the FA-AML MSCs may be an essential
initiating event in FA leukaemogenesis, which progresses exclusively to myeloid leukaemia
(Bagby & Alter, 2006; Dong et al, 2015), as the expansion can enlarge the pool of
transformable cells.

Author Manuscript

Over-production of PGs in FA-AML MSCs is correlated with HSPC/myeloid expansion in
NSGS recipients
To identify the molecular mechanism underlying the effect of the FA MSCs on the fate of
co-cultured HSPCs, we turned our attention to metabolic components, as metabolites
produced by MSCs in the BM niche are vital to normal HSC functions and play crucial roles
in leukaemic transformation (Raaijmakers et al, 2010; Morrison & Scadden, 2014). We
performed untargeted metabolic profiling to analyse the metabolome of BM-derived MSCs
from HD and FA patients at the disease stages of BM failure (FA-BMF), MDS (FA-MDS)
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and AML (FA-AML), by LC-Q-TOF-MS) (Schultz et al, 2013). This global metabolic
platform identified 934–2252 metabolites upregulated and 728–1091 metabolites
downregulated in FA MSCs compared to HD MSCs (Fig 2A, B). Among the de-regulated
metabolites, PGs, which are an important component of the inflammatory mesenchymal
secretome (Fontaine et al, 2016), were the only metabolites that are progressively elevated in
FA-MDS and FA-AML MSCs (Fig 2C; data not shown). Furthermore, using PG-specific
ELISA kits, we found that intracellular levels of several PGs, namely PGD2, PGE1 and
PGE2, were indeed increased in the MSCs from FA-BMF, FA-MDS and FA-AML patients
compared to those from HD (Fig 2D).
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To determine whether the effects of FA-AML MSCs on HSPC/myeloid expansion in the
transplanted recipients were indeed mediated by these MSC-derived PGs, we employed two
approaches: (i) blocking PG synthesis by a COX2i, celecoxib (Rezavand et al, 2013); (ii)
treating the transplanted recipients with a long-acting agonist of PGE2, 16–16 dimethyl
PGE2 (dmPGE2; Goessling et al, 2009) (Fig 3A). We first confirmed that the levels of PGD2
and PGE2 in the celecoxib-treated FA-AML MSCs were significantly reduced (Fig 3B).
Strikingly, celecoxib treatment almost completely abolished the otherwise HSPC/myeloid
expansion observed in FA-AML MSC-co-cultured cells (Fig 3C). In the second experiment,
we found that while it did not completely recapitulate the effect of the FA-AML MSCs,
dmPGE2 treatment induced HSPC/myeloid expansion in NSGS recipients (Fig 3D).
Together, these studies identify the inflammatory COX2-PG secretome as a potential
mediator of the effects of the FA-AML MSCs on HSPC/myeloid expansion.
The link between AML-MSC COX2-PG secretome and NR4A-Treg signalling

Author Manuscript
Author Manuscript

To identify the signalling pathways that specifically mediate the effect of the leukaemic
mesenchymal COX2-PG secretome, we performed two sets of gene-expression profiling
(GEP) by RNA-seq analysis. GEP 1 used co-cultured cells on HD, FA-BMF or FA-AML
MSCs and GEP 2 used cells co-cultured on FA-AML MSCs treated with or without COX2i,
or on HD MSCs stably expressing COX2 (Figure S1A). We noted that treatment of FAAML MSCs with the COX2i, celecoxib, reduced several PGs to the levels comparable to
those in HD MSCs (Fig 3B), and that HD MSCs transfected with COX2 not only expressed
much higher levels of both PTGS2 mRNA (Figure S1B) and COX2 protein (Figure S1C) but
also increased PGE2 biosynthesis (Figure S1D) than those transfected with the empty vector
(Figure S1C). Pathway analysis identified 10 top pathways that were shared by both sets of
GEP, with signalling receptor activity, WNT signalling and regulatory T cell differentiation
pathways most significantly affected (Figure S1E). Specifically, genes involved in those
pathways include the NR4A nuclear hormone TF family (NR4A2 [NURR1], NR4A3
[NOR1], NR4A1 [NUR77], PRL, MMP13, EGR1, JUNB, PLK2; Ramirez-Herrick et al,
2011), WNT/β-catenin signalling (LEF1, SOX9, WNT5A, FZD9, FHL2, DLG2, CTNNB1,
PTGS2, CCND1, MMP9; Hovanes et al, 2001) and Treg function (FOXP3, CTLA4,
LGALS3, IL2RA / ISG20 [CD25], CCR7, TNFRSF18 [GITR], TIAF1, IL2, CYSLTR1,
LTB4R; Marson et al, 2007; Zheng et al, 2007) pathways (Figure S1E, F). These three
pathways are known to be involved in leukaemogenesis (Nishikawa & Sakaguchi, 2010;
Mohan et al, 2012), and functionally related to PGs, particularly PGE2 (Smith et al, 2000;
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Goessling et al, 2009; Smyth et al, 2009; Durand & Zon, 2010; Hoggatt & Pelus, 2010;
Fontaine et al, 2016).
Given that inflammatory PGs can induce the expression of the NR4A TFs (Ramirez-Herrick
et al, 2011), we further examined whether there was a potential link between the AML-MSC
COX2-PG secretome and NR4A signalling. We found that reduced secretion of PGs by
mesenchymal inhibition of COX2 was correlated with decreased expression of the NR4A
TFs and Treg genes (FOXP3 and CTLA4) in the AML MSC-cocultured CD34+ cells (Fig
4A–C). Conversely, pre-treatment with dmPGE2 increased expression of the NF4A TFs and
Treg genes in HD MSC-cocultured CD34+ cells but had no further effect on FA-AML MSC
co-cultured CD34+ cells (Fig 4D, E). These results provide initial evidence linking the
AML-MSC COX2-PG secretome to NR4A signalling.

Author Manuscript

Crosstalk between NR4A and WNT signalling in the regulation of anti-leukaemia T-effector
cells

Author Manuscript

The canonical WNT pathway involves post-translational mechanisms that prevent
proteasomal degradation of the proto-oncogene β-catenin (CTNNB1) and allow it to bind to
the TCF-LEF family of TFs for transactivation of the WNT target genes (Behrens et al,
1996). Our gene-profiling studies showed that CTNNB1 mRNA was significantly increased
in CD34+ cells co-cultured on FA AML-derived MSCs (Figure S1). Given that NR4A TFs
regulate CTNNB1 transcription (Rajalin & Aarnisalo, 2011; Smith et al, 2011; Han & Cao,
2012), we thus determined whether the AML-MSC COX2-PG secretome could induce
crosstalk between NR4A TFs and WNT/β-catenin signalling in the AML MSC-co-cultured
HSPCs. CTNNB1 promoter activity was measured using a CTNNB1-luciferease reporter
(−591 to +147; Nollet et al, 1996), in response to ectopic expression of the NR4A TFs.
HEK293 cells transfected with the CTNNB1-luci-ferease reporter showed marginal
luciferase activity induced by ectopic expression of individual NR4A TFs but a synergistic
enhancement of the reporter activity when both NR4A1 and NR4A2 (but not NR4A3)
expression vectors were present (Fig 5A), suggesting that NR4A1 and NR4A2 were acting
in concert to activate the CTNNB1 promoter. By using a WNT GFP reporter assay (Fuerer
& Nusse, 2010; Sertorio et al, 2016), we confirmed the significantly enhanced WNT
activation in CD34+ cells co-cultured with FA-AML MSCs compared to those co-cultured
with HD-MSCs (Fig 5B).
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To test the functional consequence of upregulated WNT/β-catenin signalling, we reduced
CTNNB1 expression by siRNA in the AML MSC-cocultured CD34+ cells (Figure S2A) and
determined the effect of CTNNB1 knockdown on regulation of anti-leukaemia T effector
cells. Consistent with upregulated FOXP3 (Fig 4), the AML MSC-cocultured HSPCs
favoured CD25+FOXP+ Treg differentiation (Fig 5C, left). Knock-down of CTNNB1 had no
effect on the frequency of Treg cells (Fig 5C, left). Strikingly, knocking down CTNNB1
significantly increased the production of CD8+CCR7+ T effector cells (Fig 5C, right), a
population known to play a major role in anti-leukaemia immunity (Nowyhed et al, 2015).
Next, we performed a semi-automated mini-cytotoxicity assay (Marson et al, 2007) to
determine specific lysis of HLA-mismatched leukaemia target cells. The results show that
the sorted co-cultured CD8+CCR7+ cells from a healthy donor (HLA-2·2+) exhibited greater
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lysis of blast cells taken from an AML patient (HLA-A2·1+) than the unsorted co-cultured
cells or total CD8+ cells (Fig 5D). Marginal lysis of the AML cells was observed for the
CD8+CCR7− T cells (data not shown). Furthermore, knocking down CTNNB1 markedly
enhanced the capacity of the sorted CD8+CCR7+ cells or total CD8+ cells to lyse the
leukaemia cells (Fig 5D).
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Similar results were obtained in NR4A1 knockdown experiments (Fig 5C, E), in which
knocking down NR4A1 (Figure S2B) significantly reduced the expression of the WNT
signalling gene CTNNB1, significantly increased CD8+CCR7+ population without affecting
Treg cell frequency (Fig 5C) and markedly enhanced the cytotoxic capacity of the sorted
CD8+CCR7+ cells or total CD8+ cells on the HLA-mismatched leukaemia cells (Fig 5E). It
is noteworthy that knocking down NR4A1 also significantly reduced the expression of the
WNT signalling gene CTNNB1, suggesting that the NR4A TFs may regulate β-catenin at
the transcription level. Taken together, our results suggest that the upregulated NR4A-WNT
signalling axis may act to attenuate anti-leukaemia immunity by blocking the production of
leukaemia-reactive CD8 cytotoxic T lymphocytes.

Discussion
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Acute myeloid leukaemia has a 5-year survival rate of 25% (Georgi et al, 2016). Clinical
evidence continues to support the need to identify novel targets and therapeutics for the
treatment of this deadly disease. Experimental evidence has clearly shown that interaction of
the leukaemic cells with the tumour microenvironment (TME) contributes to de novo drug
resistance and, probably, failure to eliminate minimal residual disease (MRD; Ossenkoppele
& Schuurhuis, 2013). However, the impact of TME-induced immune response in mediating
MRD following standard of care treatment and BMT is currently less clear. Here we
investigated the regulation of the interaction between leukaemic mesenchymal niche and
normal HSPCs and identified a novel COX2/PG-NR4A/WNT signalling axis, connecting
inflammation, cellular metabolism and cancer immunity. There are several findings that
highlight the significance of our study: (i) The recipients transplanted with normal HSPCs
co-cultured on the FA-AML MSCs exhibited HSPC and myeloid expansion; (ii) PGs were
progressively elevated in FA-MDS and FA-AML MSCs; (iii) Treatment with the COX2i,
celecoxib, reduced PGs produced by FA-AML MSCs and abolished HSPC/myeloid
expansion in FA-AML MSC-co-cultured cells; (iv) Gene-expression profiling identified
NR4A/WNT/Treg signalling pathways mediating the effect of the AML-MSC COX2-PG
secretome; (v) Reduced secretion of PGs by mesenchymal inhibition of COX2 led to
decreased expression of NR4A TFs and the Treg genes, FOXP3 and CTLA4, in the AMLMSC-cocultured CD34+ cells; (vi) The upregulated NR4A-WNT/β-catenin signalling acted
to attenuate anti-leukaemic immunity by upregulating Tregs and blocking the production of
leukaemia-reactive CD8 cytotoxic T lymphocytes.
One intriguing finding of the present study is our observation that the ability of FA-BMFderived MSCs to support in vitro HSPC proliferation and in vivo haematopoietic
repopulation is not compromised. Specifically, we showed that total normal human CD34+
and CFU-C were significantly increased on all three groups of MSCs, with FA-AML derived
MSCs showing the greatest ability to support expansion of normal human BM HSPCs (Table
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S1). This is in striking difference with previous studies describing phenotypic
haematopoiesis-supportive defects of MSCs from Fancc; Fancg double KO, Fanca−/− and
Fancc−/− mice in an in vitro co-culture system in which HSPCs from wild type mice were
seeded on these FA MSCs (Zhou et al, 2017; Xu et al, 2018). It is noteworthy that the results
of these in vitro studies in FA mouse models have not been confirmed in vivo. The
discrepancy in the results from the in vitro co-culture studies may be due to several factors.
First, the haematopoietic supportive property may be different between mice and humans.
Second, the co-culture conditions are different: the mouse studies used cytokine-free MSC
medium; whereas our human studies used serum-free medium containing SCF, FLT3 ligand,
TPO and G-CSF. Finally, there generally is a phenotypic variety among patients, which may
contribute functional differences between mice and humans in particular in vitro
experiments.
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Mesenchymal PGs have been shown to be important components of the stromal secretome
(Fontaine et al, 2016), and play major roles in inflammation and immune response (Schepers
et al, 2013). Among them, PGE2 is known to play critical roles in HSC expansion and
engraftment in the context of HSCT (Durand & Zon, 2010; Hoggatt & Pelus, 2010). By
unbiased metabolomics analysis, here we identified PGs as the only metabolites that were
progressively elevated during FA disease progression (Fig 2). Co-culture of CD34+ cells
from HD on high PG-producing FA-AML MSCs caused HPSC and myeloid expansion in
transplanted recipients. Reduction of PGs subsequent to pharmacological and genetic
inhibition of the inflammatory COX2 in AML MSCs ameliorated HSPC and myeloid
expansion in transplanted recipients (Fig 3). These results are in line with previous studies,
that clinical human leukaemia uniformly expresses COX2 in circulating blasts (Bernard et
al, 2008) and COX2 selective inhibitors have shown potential as immunotherapeutics for
haematological malignancies (Lilly et al, 2004; Ramon et al, 2013). Therefore, targeting the
COX2-PG signalling axis may present an effective strategy for the treatment of many
haematological malignancies.
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Members of the orphan nuclear hormone receptor NR4A subfamily, composed of closely
related molecules NR4A1 (NUR77), NR4A2 (NURR1) and NR4A3 (NOR1), are early
response genes induced by a variety of stimuli including growth factors, inflammation,
cytokines, peptide hormones and cellular stress (Maxwell & Muscat, 2006). Their
expression is highly enriched in Treg cells (Lin et al, 2007; Moran et al, 2011), which play
an important role in the establishment and maintenance of immune tolerance after allogeneic
HSCT (Rezvani et al, 2006; Rieger et al, 2006). Recent studies have shown that the NR4A
family of TFs transactivate expression of FOXP3 and are critical for the generation of Tregs
(Bandukwala & Rao, 2013; Sekiya et al, 2013; Michonneau et al, 2016). Consistent with
these observations, our transcriptomic studies showed dysregulated genes involved in NR4A
nuclear hormone TF family and Treg function in FA-AML MSC co-cultured CD34+ cells.
Consistently, reduced biosynthesis of PGs by mesenchymal inhibition of COX2 decreased
expression of the NR4A TFs and the Treg genes, FOXP3 and CTLA4, in the AML MSCcocultured CD34+ cells (Fig 4). It is in this context that our results provide the first line of
evidence linking the AML-MSC COX2-PG secretome to the NR4A-Treg signalling axis and
thus support a function role of altered NR4A signalling in Treg biology.
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The remarkable activity of donor T cells against malignant cells in the context of allogeneic
HSCT is arguably the most potent clinical immunotherapy for cancer (van den Brink et al,
2002). In fact, the success of HSCT relies on the donor CTL-mediated graft-versusleukaemia (GVL) effect (Michonneau et al, 2016). Therefore, induction of functional CTLs
is one of the major goals for stem cell therapy. Recent studies have demonstrated an
essential role of the WNT signalling for CTL manipulation in autoimmune diseases and
immune therapy for certain cancers (Jeannet et al, 2010; Xiao et al, 2013). Our
transcriptomic studies showed dysregulated expression of genes involved in NR4A TFs and
WNT pathways, which is associated with expansion of Tregs and a reduction of the
leukaemia-reactive CD8+CCR7+ pool. Mechanistically, we showed that NR4A1 and NR4A2
acted in concert to activate the CTNNB1 promoter (Fig 5). Although further studies are
needed to elucidate the exact mechanism, our findings that knocking down CTNNB1 or
NR4A1 significantly increased production of the leukaemia-reactive CD8+CCR7+
population (Nowyhed et al, 2015), and markedly enhanced the capacity of the sorted
CD8+CCR7+ cells to lyse leukaemia cells (Fig 5D, E), shed new light on understanding the
role of leukaemic niche factors in regulating donor anti-leukaemia immunity in HSCT.
Defining niche components and the molecular mechanisms by which these factors work to
regulate haematopoiesis provides opportunities to understand how disordered niche function
could contribute to disease, and reveal potential therapies for patients with leukaemia and
other haematological malignancies (Schepers et al, 2013). Our present findings identify the
specific interactions between leukaemic mesenchymal niche and donor HSPCs to orchestrate
a novel COX2/PG/NR4A/WNT signalling axis, connecting inflammation, cellular
metabolism and cancer immunity, and contribute to better understanding of the underlying
mechanisms in HSCT-associated disease relapse.
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NSGS mice transplanted with normal cells co-cultured on FA-AML MSCs exhibit
haematopoietic stem and progenitor cells and myeloid expansion. 5 × 105 normal bone
marrow (BM) cells co-cultured on mesenchymal stromal cells (MSCs) from healthy donors
(HD), Fanconi anaemia (FA) patients with cytopenias but no cancer (FA-BMF) or FA
patients with acute myeloid leukaemia (FA-AML) (3–5 BM samples for each group) were
transplanted into sublethally-irradiated NSGS mice. Recipients were intraperitoneally (i.p.)
injected with the GVHD inhibitor OKT3 (10 μg/kg) at 24 h and 1 week after transplant. BM
cells were subjected to flow cytometry analysis for human cell content at 12 weeks posttransplant. (A) Representative flow cytometry plots of total human engraftment (hCD45+;
left), CD34+ (middle) and myeloid (CD33+)/lymphoid (CD19+) cells. (B) Quantification of
human cell content by flow cytometry analysis depicted in (A). Results are means ± SD of
three independent experiments (n = 9–12 for each group). **P < 0·01. [Colour figure can be
viewed at wileyonlinelibrary.com]
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Elevated levels of prostaglandins (PGs) in FA-MDS and FA-AML MSCs. Liquid
chromatography-mass spectroscopy -based untargeted metabolomics analysis of
mesenchymal stromal cells (MSCs) from healthy donors (HD), Fanconi anaemia (FA)
patients with cytopenias but no cancer (FA-BMF), FA patients with myelodysplastic
syndrome (FA-MDS) or FA patients with acute myeloid leukaemia (FA-AML). (A) Cloud
plot presentation of metabolite features of FA-MDS versus HD MSCs and FA-AML versus
HD MSCs with fold change ≥3 and P ≤ 0·01. The statistical significance of the fold change
was calculated by a Welch t test with unequal variances. Upregulated features (features that
have a positive fold change) are graphed above the x-axis in green while downregulated
features (features that have a negative fold change) are graphed below the x-axis in red. The
x-axis represents retention time. The y-axis represents mass-to-charge (m/z) ratio. Features
with higher fold change have larger radii. Features with lower P-value have higher colour
intensity. (B) Venn diagram demonstrating the separate and overlapping metabolite features
in BMF, MDS and AML MSCs compared to HD MSCs showing both upregulated and
downregulated metabolites with fold change ≥3 and P value ≤0·01. (C) The levels of the
metabolites in the Arachidonic acid metabolism pathway are shown. (D) Elevated level of
the indicated PGs in MSCs analysed by enzyme-linked immunosorbent assay. Results are
means ± SD of three independent experiments (n = 9 for each group). *P < 0·05; **P < 0·01.
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The AML-MSC COX2-PG secretome promotes HSPC/myeloid expansion in humanized
recipients. (A) Schematic representation of the experimental design. Reduction of
prostaglandin (PG) biosynthesis by COX2 inhibitor (COX2i) in mesenchymal stromal cells
(MSCs) from Fanconi anaemia (FA) patients with acute myeloid leukaemia (FA-AML). FAAML MSCs were pre-treated with COX2i (celecoxib, 10 μmol/l) for 2 h followed by coculture with normal bone marrow (BM) CD34+ cells for two weeks. The progenies were
then transplanted into sublethally-irradiated NSGS recipients. In another set of experiments,
normal BM CD34+ cells were co-cultured on healthy donor (HD) MSCs for 2 weeks
followed by BM transplantation into NSGS mice. The recipients were then injected with 16–
16 dimethyl-PGE2 (dmPGE2; 10 μg/kg body weight) twice per day for 7 days starting at 24
h after transplantation. (B) COX2i celecoxib reduces PG production in FA-AML MSCs. FAAML MSCs were pre-treated with COX2i (COX2i; celecoxib, 10 μmol/l) or vehicle (5%
dimethyl sulphoxide) for 2 h. The levels of the indicated PGs in MSCs were measured by
enzyme-linked immunosorbent assay. Results are means ± SD of three independent
experiments (n = 9 for each group). (C) COX2i celecoxib prevents haematopoietic stem and
progenitor cell (HSPC)/myeloid expansion of FA-AML MSC-co-cultured cells. Co-cultured
cells described in (B) were transplant into sublethally-irradiated NSGS mice (5 × 105 cells/
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mouse; n = 6). Total human engraftment (hCD45+), HSPCs (CD34+) and myeloid (CD33+)/
lymphoid (CD19+) cells were analysed by flow cytometry eight weeks post-transplant.
Results are means ± SD of three independent experiments (n = 9–12 for each group). (D)
dmPGE2 treatment induces HSPC/myeloid expansion in NSGS recipients. The NSGS
recipient mice transplanted with HD MSC co-cultured cells were subjected to daily i.p.
injection of dmPGE2 (10 μg/kg body weight) or vehicle (Neat oil) twice per day for 7 days
starting at 24 h post-transplant. Total human engraftment (hCD45+), HSPCs (CD34+) and
myeloid (CD33+)/lymphoid (CD19+) cells of the recipients were analysed by flow
cytometry. Results are means ± SD of three independent experiments (n = 9–12 for each
group). *P < 0·05, **P <0·01. [Colour figure can be viewed at wileyonlinelibrary.com]
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Fig 4.
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The link between AML-MSC COX2-PG secretome and NR4A-Treg signalling. (A)
Mesenchymal inhibition of COX2 reduces the secretion of prostaglandins (PGs).
Mesenchymal stromal cells (MSCs) from Fanconi anaemia (FA) patients with acute myeloid
leukaemia (FA-AML) were pre-treated with COX2 inhibitor (celecoxib, 10 μmol/l) or
vehicle (5% dimethyl sulphoxide) for 2 h, and the levels of the indicated PGs in the culture
medium were measured by enzyme-linked immunosorbent assay. Results are means ± SD of
three independent experiments (n = 9 for each group). (B) Mesenchymal inhibition of COX2
reduces the expression of the NR4A transcription factors (TFs) in co-cultured CD34+ cells.
The MSCs in (A) were co-cultured with normal CD34+ cells for 2 weeks and expression of
the three NR4A TF genes was determined by real-time polymerase chain reaction (PCR).
Results are means ± SD of three independent experiments (n = 9 for each group). (C)
Mesenchymal inhibition of COX2 reduces the expression of Treg genes in co-cultured
CD34+ cells. The MSCs in (A) were co-cultured with normal CD34+ cells for 2 weeks and
expression of FOXP3 and CTLA4 was determined by real-time PCR. The normal CD34+
cells were from 12 healthy donors. Results are means ± SD of three independent
experiments (n = 9 for each group). (D) 16–16 dimethyl-PGE2 (dmPGE2) treatment
increases the expression of the NR4A TF genes in co-cultured CD34+ cells. MSCs derived
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from HD were pre-treated with dmPGE2 followed by co-culture with normal CD34+ cells
for 2 weeks. The expression of the three NR4A TF genes was determined by real-time PCR.
Results are means ± SD of three independent experiments (n = 9 for each group). (E)
dmPGE2 treatment increases the expression of Treg genes in co-cultured CD34+ cells. Cocultured normal CD34+ cells described in (D) were subjected to real-time PCR analysis for
FOXP3 and CTLA4. The normal CD34+ cells were from 12 healthy donors. Samples were
normalized to the level of GAPDH mRNA. Results are means ± SD of three independent
experiments (n = 9 for each group). *P < 0·05, **P < 0·01. [Colour figure can be viewed at
wileyonlinelibrary.com]
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Crosstalk between NR4A and WNT signalling in regulation of anti-leukaemia T effector
cells. (A) NR4A1 and NR4A2 act synergistically to enhance CTNNB1 reporter activity.
HEK293 cells expressing a CTNNB1 reporter construct containing −591 to +147 of the
proximal CTNNB1 promoter were co-transfected with the indicated combinations of the
NR4A transcription factors (TFs). Twenty-four hours after transfection, cells were analysed
for luciferase activity. Results are means ± SD of three independent experiments (n = 9 for
each group). (B) Enhanced WNT activation in CD34+ cells co-cultured with mesenchymal
stromal cells (MSCs) from Fanconi anaemia (FA) patients with acute myeloid leukaemia
(FA-AML). CD34+ cells were transduced with 7TGC-eGFP WNT reporter lentivirus
followed by co-culture with HD-MSC or FA-AML-MSC for two weeks. Percentage of GFP+
cells were determined by Flow cytometry. Results are means ± SD of three independent
experiments (n = 9 for each group). (C) CTNNB1 or NR4A1 knockdown reduces
CD8+CCR7+ T cells. Normal CD34+ cells were transfected with 25 nmol/l siGenome
SMARTpool siRNAs for CTNNB1, NR4A1 or non-targeted Scramble. After 48 h, cells
were co-cultured with FA-AML MSCs for 2 weeks and subjected to by flow cytometry
analysis for different T-cell subsets. The graphs show quantification of the indicated T-cell
subsets in gated CD3CD4 T cells (CD25+FOXP3+; left) or gated CD3CD8 T cells
(CD8+CCR7+; right). Results are means ± SD of three independent experiments (n = 9 for
each group). (D, E) CTNNB1 or NR4A1 knockdown rescues anti-leukaemia immunity.
CD8+ or CD8+CCR7+ cells were sorted by FACS. The indicated T-cell subsets or non-sorted
cells expressing Scramble shRNA or shRNA targeting CTNNB1 (D) or NR4A1 (E) were
then plated with bone marrow cells from HLA-mismatched AML patients in a 4 h
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cytotoxicity assay at Effector:Target (E:T) ratios from 20:1 to 2–5:1. Data were pooled from
two separate experiments, and six replicate wells were used for each dilution of effector
cells. Data are displayed as mean specific lysis ± SD. Results are means ± SD of three
independent experiments (n = 9 for each group). *P < 0·05, **P < 0·01. [Colour figure can
be viewed at wileyonlinelibrary.com]
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